Trevi Therapeutics Files Q1 2025 10-Q
Ticker: TRVI · Form: 10-Q · Filed: May 8, 2025 · CIK: 1563880
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Trevi Therapeutics filed its Q1 2025 10-Q. Financials and operations update.
AI Summary
Trevi Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations. Key financial data and disclosures related to its business operations and strategic initiatives are detailed within the filing.
Why It Matters
This filing provides investors with an update on Trevi Therapeutics' financial performance and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Trevi Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Trevi Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- 001-38886 (dollar_amount) — SEC File Number
FAQ
What is Trevi Therapeutics' primary business focus?
Trevi Therapeutics is focused on the pharmaceutical preparations industry, as indicated by its SIC code [2834].
When does Trevi Therapeutics' fiscal year end?
Trevi Therapeutics' fiscal year ends on December 31st.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 8, 2025.
What is the reporting period for this 10-Q?
The reporting period for this 10-Q is the quarter ending March 31, 2025.
Where is Trevi Therapeutics headquartered?
Trevi Therapeutics is headquartered in New Haven, CT, with its business address at 195 Church Street, 14th Floor.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Trevi Therapeutics, Inc. (TRVI).